多肽介导的给药系统在肝癌靶向治疗中的研究进展  

Progress of Peptide-modified Drug Delivery System for Targeted Therapy of Liver Cancer

作　　者：王梦梦 王欢 欧阳湖 杜珊 吴舒蕾 陈思维 贺冬秀 WANG Meng-meng;WANG Huan;OUYANG Hu;DU Shan;WU Shu-lei;CHEN Siwei;HE Dong-xiu(School of Pharmacy,University of South China,Institution of Pharmacy&Pharmacology,University of South China,Hengyang 421001,China)

机构地区：[1]南华大学药学院南华大学药物药理研究所

出　　处：《肿瘤学杂志》2019年第10期876-881,共6页Journal of Chinese Oncology

基　　金：湖南省教育厅创新平台开放基金项目(16K079);南华大学2018年度大学生研究性学习和创新性实验计划项目

摘　　要：肝癌是常见的恶性肿瘤,也是癌症相关死亡的重要原因之一。多肽具有尺寸小、合成修饰容易、免疫原性低等优点。因此,多肽修饰的靶向给药系统近年来引起研究者们越来越多的关注。多肽介导的纳米药物传递系统(脂质体、聚合物胶束和纳米粒等)能有效地将药物传递至肝癌细胞,提高肿瘤部位的药物浓度从而增强药物疗效,减少不良反应。多肽介导的靶向药物传递系统在肝癌靶向治疗中发挥着重要作用。全文就近5年来多肽介导的给药系统在肝癌靶向治疗中的应用研究进展做一简要综述,以期为肝癌靶向制剂的研发提供参考。Liver cancer is a common malignant tumor and one of the main causes of cancer-related deaths. Peptides exhibit significant advantages of small size,easy synthesis and modification,as well as low immunogenicity. Herein,peptide-modified targeted drug delivery systems have drawn increasing attention from scientists in recent years. Peptide-modified drug delivery nanosystems,including liposomes,polymer micelles,nanoparticles,can deliver drugs more efficiently to liver cancer cells and increase drug concentration,to improve drug efficacy and reduce adverse reactions. Peptide-mediated targeted drug delivery system may play a important role in targeted therapy for liver cancer. In this review,the research progress of the peptide-mediated drug delivery system and its application for targeted therapy for liver cancer is reviewed.

关 键 词：多肽 肝肿瘤 靶向治疗 研究进展 

分 类 号：R735.7[医药卫生—肿瘤]